Volume | 6,464 |
|
|||||
News | - | ||||||
Day High | 0.27495 | Low High |
|||||
Day Low | 0.25 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Ayala Pharmaceuticals Inc (PK) | ADXS | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.25 | 0.25 | 0.27495 | 0.2501 | 0.262475 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
36 | 6,464 | $ 0.251092 | $ 1,623 | - | 0.135 - 1.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:34:13 | 1,000 | $ 0.2501 | USD |
Ayala Pharmaceuticals Inc (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.16M | 4.84M | 1.80M | 13k | -48.07M | -9.94 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ayala Pharmaceuticals (PK) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADXS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.2505 | 0.2999 | 0.25 | 0.2684766 | 3,519 | -0.0004 | -0.16% |
1 Month | 0.30 | 0.3196 | 0.20 | 0.2692724 | 7,755 | -0.0499 | -16.63% |
3 Months | 0.6215 | 0.72 | 0.135 | 0.3844859 | 10,385 | -0.3714 | -59.76% |
6 Months | 0.6601 | 1.49 | 0.135 | 0.786611 | 17,599 | -0.41 | -62.11% |
1 Year | 0.97 | 1.95 | 0.135 | 0.8353666 | 11,368 | -0.7199 | -74.22% |
3 Years | 0.158 | 4.50 | 0.0514 | 0.1761892 | 178,527 | 0.0921 | 58.29% |
5 Years | 0.158 | 4.50 | 0.0514 | 0.1761892 | 178,527 | 0.0921 | 58.29% |
Ayala Pharmaceuticals (PK) Description
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma (ACC), T-cell Acute Lymphoblastic Leukemia (T-ALL), and Desmoid Tumors. |